[Effects of nonoxinol 9 on RFLP typing of postcoital vaginal smears].
Nonoxinol 9 effectively inactivates high titres of HIV in vitro, which suggest its use for reducing HIV-transmission via sexual intercourse. Therefore, the suggestion has been made for the treatment of sexual assault victims with a topical anti-HIV agent such as nonoxinol 9 as soon as possible after a sexual assault has occurred. From the forensic point of view it becomes pertinent to determine whether or not nonoxinol 9 would have an adverse effect on the high-molecular weight deoxyribonucleic acid (DNA) in vaginal swabs and thereby impact RFLP results. The study demonstrates that nonoxinol 9 does not have a negative effect on the ability to produce RFLP patterns. Therefore, the early administration of the topical anti-HIV agent nonoxinol 9 has to be considered as an important step in the medical treatment of sexual assault victims.
Institut für Rechtsmedizin, Universität Bern.
M
M
Hochmeister
E
E
Miescher
W
W
Lipowec
U V
UV
Borer
R
R
Dirnhofer
D004247:DNA / Q000235:genetics*; D015252:Deoxyribonucleases, Type II Site-Specific / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D012150:Polymorphism, Restriction Fragment Length; D012742:Sex Offenses / Q000331:legislation & jurisprudence*; D014622:Vaginal Creams, Foams, and Jellies / Q000494:pharmacology*; D014626:Vaginal Smears
D014622:Vaginal Creams, Foams, and Jellies; D004247:DNA; D015252:Deoxyribonucleases, Type II Site-Specific; C024403:GGCC-specific type II deoxyribonucleases
Auswirkungen von Nonoxinol 9 auf die RFLP-Typisierung postkoitaler Vaginalabstriche.